-
Review
-
Korean J Med. 2006;71(1):175-175.
- High FDG uptake on PET in patients with advanced NSCLC on platinum-based combination chemotherapy
-
Kyung-Hun Lee, Se-Hoon Lee, Dong-Wan Kim, Won Jun Kang, June-Key Chung, Seock-Ah Im, Tae-You Kim, Young Whan Kim, Yung-Jue Bang, Dae Seog Heo
-
.
- High FDG uptake on PET in patients with advanced NSCLC on platinum-based combination chemotherapy
-
, , , , , , , , ,
-
1Department of Internal Medicine, Hanyang University College of Medicine, Seoul; 2Department of Life Science, Postech Biotech Center, Pohang University of Science and Technology, Pohang, Korea
-
- Abstract
- Purpose
To evaluate response and survival for platinum-based combination chemotherapy in chemo-naive patients with
non-small-cell lung cancer (NSCLC) according to pretreatment standardized uptake values (SUVs) by fluorodeoxyglucose
positron emission tomography (FDG PET). Experimental Design Patients with advanced NSCLC who had not previously
received chemotherapy were eligible. Response rates and survivals were analyzed according to maximal SUVs [low (≤ 7.5) vs.
high (> 7.5), where 7.5 was the median value] before the first cycle of chemotherapy. Results Eighty-five consecutive patients
were included in the study. Patients with high SUV tumors exhibited significantly higher response rates (34.1% for low SUVs
vs. 61.0% for high SUVs, P = 0.013). Other factors including sex, age, histology, performance status, number of involved organs,
regimens used, and disease stage did not affect response. However, high SUVs were related with a shorter response duration
(279 days for low SUVs vs. 141 days for high SUVs, P = 0.003) and time-to-progression (282 days for low SUVs vs. 169 days
for high SUVs, P = 0.015). Overall survival was unaffected by maximal SUVs (623 days for low SUVs vs. 464 days for high
SUVs, P = 0.431). Conclusions Patients having NSCLC with high maximal SUVs showed a better response to platinum-based
combination chemotherapy, but had a shorter time-to-progression. Tumor glucose metabolism, as determined by SUVs on FDG
PET, was found to discriminate NSCLC subsets with different clinical and biological features.
Keywords :
